Our novel therapies for retinal disease are designed to restore vision, stop progression of underlying disease, and require fewer treatments.
Location: United States, California, Palo Alto
Employees: 51-200
Total raised: $34M
Founded date: 2009
Investors 3
| Date | Name | Website |
| - | Rivas Capi... | rivascap.c... |
| - | Perceptive... | perceptive... |
| - | StartX | startx.com |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 12.01.2016 | Series B | $34M | - |
Mentions in press and media 8
| Date | Title | Description | Source |
| 13.03.2024 | ‘Insurgent’ food and beverage brands to watch | NEW YORK — The consultancy Bain & Co. has published a list of food and beverage “insurgent brand... | foodbusine... |
| 11.03.2024 | Women In Trucking Association Names 2024 Top Women to Watch ... | 2024 Top Women to Watch in Transportation The Women In Trucking Association (WIT) announced today it... | prweb.com/... |
| 09.08.2022 | US weighs new route of administration for monkeypox va... | Kodiak Sciences may have failed to show that its anti-VEGF drug is just as good as Regeneron’s Eylea... | endpts.com... |
| 01.09.2021 | Kodiak Sciences : Announces New Long-Term Performance Incent... | PALO ALTO, Calif., Sept. 1, 2021 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceut... | marketscre... |
| 15.02.2021 | Kodiak Sciences : Corporate Presentation February 2021 | SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS These slides contain forward-looking statements an... | marketscre... |
| 26.04.2018 | Kodiak Sciences Closes $33M Mezzanine Private Financing | Kodiak Sciences Inc., a Palo Alto, CA-based development-stage biopharmaceutical company specializing... | finsmes.co... |
| 12.01.2016 | Kodiak Sciences Closes $34M Series B Financing | Kodiak Sciences Inc., a Palo Alto, CA-based biopharmaceutical company designing and developing novel... | finsmes.co... |
| - | Kodiak Sciences’ trial failure clouds eye drug’s prospects f... | Kodiak Sciences aims to offer patients an eye drug with a dosing edge over a blockbuster medicine fr... | medcitynew... |